Insilico Medicine, Human Longevity Partner for Longevity Foundation Model

By Bio-IT World Staff

May 28, 2026 | Insilico Medicine and a Human Longevity spinout announced a strategic collaboration yesterday to develop large-scale foundation models for human longevity science capable of predicting disease risk, understanding aging biology, and accelerating the development of preventive and therapeutic interventions to extend healthy human lifespan.

Human Longevity announced the creation of a new company, Human Life Foundation Models, Inc. (HLFM), in conjunction with the multi-year and multi-million dollar framework that will address the global longevity market, which UBS estimates will grow from approximately $5.3 trillion to nearly $8 trillion by 2030.

Human Life Foundation Models will coordinate the development and training of next-generation biomedical world models within secure decentralized environments, while Insilico contributes advanced AI architecture, benchmark systems, and model teacher infrastructure. The goal is to enable predictive health insights at global scale while respecting local regulatory, ethical, and data sovereignty requirements.

At the 2025 Bio-IT World Conference and Expo, Alex Zhavoronkov, CEO and founder of Insilico Medicine, was already focused on aging. "Currently, my problem in life is that there are so many ways to diagnose aging. You can look at yourself in the mirror or in the passport. But there are very, very few ways to intervene in aging," Zhavoronkov explained last year.

And Human Longevity has spent more than a decade building one of the world's largest integrated datasets of genomics, imaging, clinical, and longitudinal health information from thousands of individuals (Bio-IT World celebrated their efforts in 2026!). HLFM's access to Human Longevity's reasoning data for health risk screening will be used to support its foundation models cognitive training process of detecting, diagnosing, and managing patient conditions.

Together, the companies aim to create a next-generation foundation model longevity platforms that can decode the biological mechanisms of aging and enable predictive healthcare shifting medicine from treating disease to preventing it.

The collaboration is designed around a privacy preserving AI architecture in which raw patient-level data remains with its original owners and custodians and is not transferred, centralized, or shared across institutions or countries, the companies say.

"Human Longevity was founded with the vision that large-scale biological data combined with artificial intelligence would fundamentally transform medicine," said Wei-Wu He, Executive Chairman of Human Longevity in the announcement. "By having HLFM partnering with Insilico Medicine to build the human life foundation models, we are taking a major step toward creating a true foundation model for human health and longevity—one that can help predict complex disease decades before it occurs and guide interventions to extend healthy lifespan."

“This collaboration is about creating a true foundation model for human health that can identify disease risks earlier, uncover novel therapeutic targets, and accelerate the discovery of longevity therapeutics with unprecedented precision," Zhavoronkov added in the same statement.

HLFM will focus on building large multimodal AI models trained on genomic, proteomic, imaging, clinical, and longitudinal health data. These models are expected to enable breakthroughs in early detection of age-related diseases, predictive health risk modeling, AI-driven longevity therapeutics discovery, and personalized interventions to extend healthy lifespan.

The companies believe the convergence of large-scale biological datasets and generative AI technologies will help unlock significant opportunities across preventive healthcare, therapeutics discovery, diagnostics, and personalized longevity interventions within the multi-trillion-dollar global longevity market.